Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jazz Pharmaceuticals plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jazz Pharmaceuticals plc's regulatory disclosures and financial reporting.
Patricia Carr submitted a Form 144 notice reporting proposed sales of Common stock and recent transactions. The filing lists restricted stock items of 342, 294, 353 and 298 shares dated 03/05/2026. It also records sales during the past three months: 1,436 shares for $268,544.91 on 03/05/2026, 1,117 shares for $213,243.45 on 02/27/2026, and 1,253 shares for $243,810.00 on 02/26/2026.
JAZZ filed a Form 144 reporting proposed and recent transactions in common stock. The filing lists restricted stock vesting dated 03/05/2026 under "Issuer" for compensation. It also lists securities sold in the past three months by Patricia Carr on 12/05/2025, 02/26/2026, and 02/27/2026 with numeric entries 4660/797783.00, 1253/243810.00, and 1117/213243.00 respectively.
ETRADE Financial Corporation submitted a Form 144 notice regarding the proposed sale of restricted common stock dated 03/05/2026 tied to compensation. The filing also lists securities sold during the past three months by Mary Elizabeth Henderson on 12/09/2025 (2,338 common; $396,314.38) and 02/26/2026 (5,343 common; $1,039,626.50).
Jazz Pharmaceuticals director Bruce C. Cozadd reported selling a total of 6,000 ordinary shares of JAZZ in open-market transactions on March 3, 2026. The sales occurred in three blocks at weighted average prices of $186.0853, $186.7340 and $187.8444, executed under a Rule 10b5-1 trading plan. Following these planned sales, Cozadd directly owns 405,796 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals submitted a Form 144 indicating intended sales of common stock through Merrill Lynch with an associated date of 03/03/2026. The filing lists stock option-related lots dated 11/01/2021 (483 shares), 12/01/2021 (2,952 shares) and 01/03/2022 (2,565 shares).
Jazz Pharmaceuticals director Norbert G. Riedel exercised stock options and sold shares on ordinary shares. On February 27, 2026, he exercised a non-qualified stock option for 3,415 shares, converting it into the same number of ordinary shares at an exercise price of $138.08 per share.
On the same date, he then sold 3,415 ordinary shares in an open-market transaction at $192.00 per share, leaving him with 7,024 ordinary shares held directly. A separate indirect position of 10,630 ordinary shares is reported as held by a trust.
Johnson Philip L reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals executive vice president and chief financial officer Philip L. Johnson reported an equity grant of 11,857 restricted stock units, each representing one ordinary share, awarded at no cash cost under the company’s 2011 Equity Incentive Plan.
The units vest in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary of that date and the remainder vesting annually over the next three years. Following this award, Johnson directly holds 62,223 ordinary shares.
Jazz Pharmaceuticals plc executive Samantha Pearce, EVP and Chief Commercial Officer, received an equity award tied to the company’s ordinary shares. She acquired 9,782 restricted stock units, with no cash paid per share, increasing her directly held stake to 52,775 ordinary shares after the transaction.
Each restricted stock unit represents a right to receive one ordinary share if it vests under the company’s 2011 Equity Incentive Plan. The award vests in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary of that date and the remainder vesting annually over the following three years.
Jazz Pharmaceuticals reported that EVP and Global Head of R&D and CMO Robert Iannone acquired 14,822 ordinary shares through a stock-based award at no cost. The grant consists of restricted stock units that convert into one ordinary share each as they vest.
The units vest in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary and the remainder over the following three years. After this award, Iannone directly holds 95,080 ordinary shares.
Jazz Pharmaceuticals SVP and Chief Accounting Officer Patricia Carr reported a mix of share awards and sales. On February 26, 2026, she received a grant of 2,223 restricted stock units under the company’s 2011 Equity Incentive Plan, with each unit convertible into one ordinary share. These units vest in equal annual installments over four years starting on March 5, 2026.
Also on February 26, 2026, she executed an open-market sale of 1,253 ordinary shares at a weighted average price of $194.1119, in multiple trades between $193.7300 and $194.4100, and shares were sold to satisfy tax obligations from vesting restricted stock units. On February 27, 2026, she sold an additional 1,117 ordinary shares at an average price of $190.9073. After these transactions, she directly held 9,235 ordinary shares.